|

Mycophenolate Mofetil Clinical Trials

26 actively recruiting trials across 11 locations

▲ +3 trials since May 2026

Also known as: (MMF), 115007-34-6, 128794-94-5, CellCept, Cellcept +3 more

Pipeline

Phase 1: 3Phase 2: 14Phase 4: 2Phase 1/2: 7

Top Sponsors

  • Fred Hutchinson Cancer Center6
  • Memorial Sloan Kettering Cancer Center4
  • National Cancer Institute (NCI)3
  • Masonic Cancer Center, University of Minnesota2
  • M.D. Anderson Cancer Center2

Indications

  • Cancer22
  • Chronic Myelomonocytic Leukemia7
  • Acute Myeloid Leukemia7
  • Acute Lymphoblastic Leukemia6
  • Myelodysplastic Syndromes6

Seattle, Washington6 trials

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Fred Hutch/University of Washington Cancer Consortium

Phase 1/2
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

Fred Hutch/University of Washington Cancer Consortium

Phase 1/2
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Fred Hutch/University of Washington Cancer Consortium

Phase 1
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Fred Hutch/University of Washington Cancer Consortium

Phase 2
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Fred Hutch/University of Washington Cancer Consortium

Phase 2
Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Fred Hutch/University of Washington Cancer Consortium

Phase 1/2

Other4 trials

Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus
Phase 4
Methods of T Cell Depletion Trial (MoTD)
Phase 2
Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis
Phase 4
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
Phase 1/2

Bethesda, Maryland3 trials

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

National Institutes of Health Clinical Center

Phase 1/2
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

National Institutes of Health Clinical Center

Phase 1
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

National Institutes of Health Clinical Center

Phase 1/2

Minneapolis, Minnesota2 trials

Allo HSCT Using RIC and PTCy for Hematological Diseases

Masonic Cancer Center at University of Minnesota

Phase 2
MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

Masonic Cancer Center at University of Minnesota

Phase 2

Basking Ridge, New Jersey2 trials

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Memorial Sloan Kettering at Basking Ridge (Consent only)

Phase 2
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 2

New York, New York2 trials

Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

Memorial Sloan Kettering Cancer Center

Phase 2
Cord Blood Transplantation in Children and Young Adults With Blood Cancer

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

Phase 2

Houston, Texas2 trials

Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

M D Anderson Cancer Center

Phase 1/2
Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation

The University of Texas M. D. Anderson Cancer Center

Phase 2

Duarte, California1 trial

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

City of Hope Medical Center

Phase 1

Loma Linda, California1 trial

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

Loma Linda University health

Phase 2

San Francisco, California1 trial

The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

University of California, San Francisco

Phase 2

Cleveland, Ohio1 trial

ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center

Phase 2

Philadephia, Pennsylvania1 trial

Two Step Haplo With Radiation Conditioning

Sidney Kimmel Cancer Center at Thomas Jefferson University

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.